Antibodies against retroviral core proteins in relation to disease outcome in patients with mycosis fungoides.
We have studied the relationship of antibodies reacting with human retroviral core proteins to the disease outcome in Finnish mycosis fungoides (MF) patients in a prospective manner. Antibodies recognizing human T-cell leukaemia/lymphoma virus I (HTLV-I) or human immunodeficiency virus type 1 (HIV-1) core proteins were found in 12 of 14 MF patients as shown by the Western blot method. The antibody reactivities showed three patterns: three patients had antibodies cross-reacting with the gag-encoded core proteins of both HTLV-I and HIV-1; seven patients showed antibodies reacting with HTLV-I core proteins only; and the sera of two patients reacted with HIV p24 core protein only. When following the clinical course of these patients, we found that the three patients with antibodies cross-reacting with both viruses had the most fulminant clinical course, and the overall duration of MF was, on average, 4 years less than in the rest of the patients. None of the patients, however, became leukaemic, or showed any other features suggestive of acute T-cell leukaemia/lymphoma (ATL). Two patients, who did not show anti-retroviral antibodies during the follow-up, had a stable disease with plaque-type skin lesions. Histological or immunohistological typing of the skin infiltrates did not correlate with the disease outcome or the above antibody patterns. Our results thus raise the possibility that an unknown retrovirus, immunologically related to the known human retroviruses, may be aetiologically linked to MF.
Ranki
A
A
Department of Dermatology, Helsinki University Central Hospital, Finland.
Niemi
K M
KM
Nieminen
P
P
Krohn
K
K
D003429:Cross Reactions / Q000276:immunology; D005260:Female; D015483:HIV Antibodies / Q000032:analysis*; D015497:HIV-1 / Q000276:immunology; D015481:HTLV-I Antibodies / Q000032:analysis*; D006801:Humans; D007124:Immunoenzyme Techniques; D007150:Immunohistochemistry; D008297:Male; D008854:Microscopy, Electron; D009182:Mycosis Fungoides / Q000276:immunology* / Q000473:pathology; D011379:Prognosis; D011446:Prospective Studies; D015682:Retroviridae Proteins, Oncogenic / Q000276:immunology*; D012878:Skin Neoplasms / Q000276:immunology* / Q000473:pathology; D014758:Viral Core Proteins / Q000276:immunology*
D015483:HIV Antibodies; D015481:HTLV-I Antibodies; D015682:Retroviridae Proteins, Oncogenic; D014758:Viral Core Proteins